王雨洁

专职科研人员

PI介绍

博士,专职科研人员、深圳市后备级人才、深圳市福田英才。主持中国博士后基金深圳市科创委面上项目。至今已发表SCI文章多篇,研究成果发表在JCI insight、cell death & disease、cancer biology & therapy等专业的国际知名杂志上。

教育背景

2006年09月-2010年06月西南大学本科

2010年09月-2016年01月北京大学博士

工作经历

2016年07月-2018年12 月深圳市第二人民医院- 博士后

2019年01月-至今深圳市第二人民医院- 专职科研人员

科研项目

1、2018年深圳市科技创新委员会基础研究项目,10万元,主持。

2、2017年中国博士后科学基金-站前特别资助,5万元,主持。

代表性成果

(1)Wang, Yujie#; Sun, Qi#; Ye, Ying#; Sun, Xiaoting; Xie, Sisi; Zhan, Yuhang; Song, Jian; Fan, Xiaoqin; Zhang, Bin;Yang, Ming; Lv, Lei; Hosaka, Kayoko; Yang, Yunlong; Nie, Guohui;FGF-2 signaling in nasopharyngeal carcinoma modulates pericyte-macrophage crosstalk and metastasis. JCI insight, 2022, 7(10): e157874.

(2)Sun, Qi#; Wang, Yujie#; Ji Hong#; Sun Xiaoting; Xie Sisi; Chen Longtian; Li Sen; Zeng Weifan; Chen Ruibo; Tang Qi; Zuo Ji; Hou Likun, Hosaka Kayoko; Lu Yongtian; Liu Ying; Ye Ying;Yang Yunlong; Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma, Cell death & disease, 2022, 13:724.

(3)Fan, Xiaoqin#; Wang, Yujie#; Song, Jian; Wu, Hanwei; Yang, Ming; Lu, Lu; Weng, Xin; Liu, Lusha; Nie, Guohui ; MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma, Cancer Biology and Therapy, 2019, 20(10): 1328-1336.

(4)Wang, Yujie#; Wang, Yuyang#; Fan, Xiaoqin; Song, Jian; Wu, Hanwei; Han, Jinghong; Lu, Lu; Weng, Xin; Nie, Guohui; ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma, Biochemical and Biophysical Research Communications, 2018, 503(3):1214-1220.

(5)Song, Jian; Wang, Yujie; Fan, Xiaoqin; Wu, Hanwei; Han, Jinghong; Yang, Ming; Lu, Lu; Nie, Guohui ; Trans-vaccenic acid inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cells via a mitochondrial-mediated apoptosis pathway, Lipids in Health and Disease,2019, 18: 0-46.

(6)Fan, Xiaoqin; Xie, Xina; Yang, Ming; Wang, Yujie; Wu, Hanwei; Deng, Tingting; Weng, Xin;Wen, Weiping; Nie, Guohui ; YBX3 Mediates the Metastasis of Nasopharyngeal Carcinoma via PI3K/AKT Signaling, Frontiers in Oncology, 2021, 11: 0-617621.